A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas
Status:
Completed
Trial end date:
2020-05-29
Target enrollment:
Participant gender:
Summary
This open-label, multicenter,dose-escalating phase I study was designed to evaluate the
safety, tolerability, pharmacokinetics and efficacy of MIL62 in Chinese patients with
relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma(NHL) for whom no treatment of
higher priority was available.